Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 5/20 | 0.60 |
| ▸ | TSHR | P16473 | 7/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29446345 | 1.00 | PLK1 (0.60) | PLK1TSHRGAASMN1; SMN2HSD17B10 | |
| SCHEMBL26851721 | 0.93 | PLK1 (0.56) | PLK1TSHRGAASMN1; SMN2HSD17B10 | |
| SCHEMBL29446334 | 0.92 | PLK1 (0.59) | PLK1TSHRGAASMN1; SMN2HSD17B10 | |
| SCHEMBL24324040 | 0.92 | PLK1 (0.59) | PLK1TSHRGAASMN1; SMN2HSD17B10 | |
| SCHEMBL26851696 | 0.91 | PLK1 (0.58) | PLK1TSHRGAASMN1; SMN2HSD17B10 | |
| SCHEMBL29446474 | 0.90 | TSHR (0.61) | PLK1TSHRGAASMN1; SMN2HSD17B10 | |
| SCHEMBL26851738 | 0.90 | TSHR (0.61) | PLK1TSHRGAASMN1; SMN2HSD17B10 | |
| SCHEMBL29446479 | 0.89 | PLK1 (0.56) | PLK1TSHRGAASMN1; SMN2HSD17B10 | |
| SCHEMBL29446367 | 0.89 | PLK1 (0.56) | PLK1TSHRGAASMN1; SMN2HSD17B10 | |
| SCHEMBL26851725 | 0.89 | PLK1 (0.56) | PLK1TSHRGAASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2022067100-A2 | PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | PLK1, PLK4, BUB1B | PLK1 1/4885TSHR 3771/4885GAA 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.